title: New guidelines for HER2+ breast cancer.
abstract: Due to the recent approval of multiple agents for HER2-positive breast cancer, the American Society of Clinical Oncology has issued new guidelines for the treatment of metastatic disease and recommendations for managing patients whose disease has spread to the brain.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000235:genetics / Q000628:therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000528:radiation effects; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D011878:Radiotherapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human